Form 8-K - Current report:
SEC Accession No. 0001628280-22-027812
Filing Date
2022-11-02
Accepted
2022-11-02 16:08:26
Documents
14
Period of Report
2022-11-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20221102.htm   iXBRL 8-K 44403
2 EX-99.1 vnda8-k1122022exhibit991.htm EX-99.1 119899
6 vandaq32019earningsca_imaga.jpg GRAPHIC 49643
  Complete submission text file 0001628280-22-027812.txt   387332

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20221102.xsd EX-101.SCH 1957
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20221102_lab.xml EX-101.LAB 24945
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20221102_pre.xml EX-101.PRE 13178
8 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20221102_htm.xml XML 11272
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 221354083
SIC: 2834 Pharmaceutical Preparations